Forensic Analysis · General / Diversified · as of Jul 30, 2026
Rxsight, Inc. (RXST)
A forensic read on Rxsight, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
4.9
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-5.4
P / E (ttm)
-14.1%
ROE
$254M
Market cap
0.00%
Dividend yield
-3.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Rxsight, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 4.9, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
311d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 176 to 311 FY2024→FY2025 (against cost of goods sold; inventory +43% vs -23% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-14.3%
FY2025
Return on invested capital.Return on invested capital is -14.3% in the latest fiscal year and rising from -41% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
+13.9%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +48% over the last 3 years to FY2025 (+13.9%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~13.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~32%.
73d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 66 to 73 days FY2024→FY2025 (receivables -22% vs revenue -4%). Receivables are creeping up relative to sales — watch the trend.
24% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 24% of revenue in FY2025 — about $0.77 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Latest Revenue$134.5M
Revenue Growth YoY-3.9%
Revenue CAGR (3yr)+40.0%
Net Margin-29.0%
Free Cash Flow$-19.3M
Return on Equity-14.1%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Rxsight, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about RXST's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown